RecruitingPhase 2NCT03587272
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
Studying Sickle cell disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Robert Nickel
- Principal Investigator
- Robert Nickel, MD, MD, MPHChildren's National Research Institute
- Intervention
- Alemtuzumab, low dose total body irradiation, Sirolimus(drug)
- Enrollment
- 100 enrolled
- Eligibility
- 2-25 years · All sexes
- Timeline
- 2018 – 2030
Study locations (7)
- Children's National Health System, Washington D.C., District of Columbia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Columbia University, New York, New York, United States
- Levine Children's Hospital, Charlotte, North Carolina, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Alberta Children's Hospital, Calgary, Alberta, Canada
- The Hospital for Sick Children, Toronto, Ontario, Canada
Collaborators
The Hospital for Sick Children · Levine Children's Hospital · Ann & Robert H Lurie Children's Hospital of Chicago · Nationwide Children's Hospital · Columbia University · The Children's Hospital at Montefiore · Alberta Children's Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03587272 on ClinicalTrials.govOther trials for Sickle cell disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07392216Functional Ovarian Reserve in Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGPHASE4NCT06979492Prophylactic Transfusion In Pregnant in Women With Sickle Cell DiseaseEmory University
- RECRUITINGNANCT07246265Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive CareUniversity Hospital, Tours
- ENROLLING BY INVITATIONPHASE2NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Fulcrum Therapeutics
- RECRUITINGPHASE1, PHASE2NCT07432867Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07222475Writing Relaxing Beats in Adolescents Who Have Sickle Cell DiseaseMayo Clinic
- RECRUITINGPHASE2NCT07224360Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)CSL Behring
- RECRUITINGPHASE3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi